Compare FFIC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | DSGN |
|---|---|---|
| Founded | 1929 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.3M | 504.7M |
| IPO Year | 1995 | 2021 |
| Metric | FFIC | DSGN |
|---|---|---|
| Price | $17.30 | $9.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 259.6K | ★ 442.6K |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | ★ 5.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $143,853,000.00 | N/A |
| Revenue This Year | $113.60 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.65 | $2.60 |
| 52 Week High | $17.79 | $10.31 |
| Indicator | FFIC | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 67.19 | 59.93 |
| Support Level | $17.13 | $8.69 |
| Resistance Level | $17.31 | $9.68 |
| Average True Range (ATR) | 0.40 | 0.72 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 69.50 | 65.80 |
Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.